Upcoming event

Tags

Abiraterone, abiraterone acetate, ACP3 PET, Active surveillance, Adjuvant, ADT, Advanced prostate cancer, Alkaline phosphatase, Alternative splicing, Androgen, Androgen deprivation therapy, Androgen pathway blockade, Androgen receptor inhibitor, Antiandrogens, Anticancer agents, apalutamide, ARCHES, Article of the Month, artificial intelligence, ASCO GU21, ASCO GU22, ASCO2026, ASCO21, ASCO26, AUA21, BHC80, Biochemical recurrence, biomarker, Biomarkers, Biopsy, Bisphosphonates, Bone metastases, BRCA1, BRCA2, CAPItello-281, capivasertib, Castrate-resistanter, Castration-resistant, Chemotherapy, Clinical trial, Clinical trials, Cohort study, COVID-19, cSP, darolutamide, Deferred treatment, Diagnosis, Disease progression, Docetaxel, EAU21, EAU22, Emission-computed, EMUC21, EMUC22, End-to-side nerve grafting, Enzalutamide, Erectile dysfunction, Erectile function, ESMO21, ESMO22, ESOU Online, ESU Masterclass, ESU Masterclasses, External beam radiotherapy, Focal therapy, Frozen section, Fusion biopsies, Genomic classifier, Genomics, Guidelines, high-risk prostate cancer, homologous recombination repair, hormone-sensitive, HORRAD, HRQL, HRR-deficient mCSPC, Image guided biopsy, Imaging, Immunohistochemistry, Index lesion, Indocyanine green, Intensity-modulated radiotherapy, Local radiotherapy, Localised, Localized, Localized prostate cancer, locally advanced prostate cancer, Lymph node excision, Lymphadenectomy, Mapping, Mass spectrometry, Masterclass, Masterclasses, mCSPC, MDV3100, Membranous urethra, Meta-analysis, Metastasis, Metastasized, Metastatic, metastatic castration-sensitive prostate cancer, metastatic hormone-sensitive prostate cancer, mHSPC, Mortality reduction, mp-MRI, MRI, Neoplasm staging, Nerve sparing, Next-generation sequencing, Nomogram, Noncastrate, Orchiectomy, Overdiagnosis, p53, Patient information, PCa21, PEACE-1 trial, pelvic lymph node dissection, Penile rehabilitation, PET/CT, Positron emission tomography, Precision medicine, prednisone, Pretreatment risk stratification, Pretreatment tables, Primary tumor treatment, PRIMARY2, Prognosis, Prognostic model, Prostasomes, prostate cancer, prostate cancer screening, Prostate screening, Prostate-specific antigen, Prostate-specific membrane antigen, Prostatic neoplasms, ProtecT trial, Proteomics, PROTEUS study, PSA, PSA flare, PSA kinetics, PSA screening, PSMA, PSMA PET/CT, PTEN, PTEN deficiency, Quality of life, Radiation therapy, Radical prostatectomy, radioligand therapy, Randomized prospective trial, Randomized trial, Randomized trials, Rapid metastasis, Rb, RB1, Receptors, Risk stratification, RNA splicing, Robotic prostatectomy, Robotic surgery, Robotic Urology, Robotics, Salvage therapy, Screening, Sentinel lymph node, Sexual quality of life, SREs, SRRM4, STAMPEDE, Stereotactic body radiotherapy, Summer read, Surgical margins, Surgical video, Surgical videos, Systematic biopsy, Systematic review, TALAPRO-3 study, talazoparib, Targeted Biopsy, TITAN, TP53, Transcriptome, Transperineal template biopsy, Tumor suppressor genes, Ultrasensitive PSA, Urinary incontinence, Urological surgery, UROonco25, Urowebinar, WCRF/AICR CUP, Webinar, Wnt, Zoledronic acid
Show all

Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer – the SALT trial

European Journal of Nuclear Medicine and Molecular Imaging, August 2020

Clinical evaluation and disease management of PI-RADS 3 lesions. Analysis from a single tertiary high-volume center

Scandinavian Journal of Urology, August 2020

A-blockers for the management of lower urinary tract symptoms in patients with prostate cancer treated with external beam radiotherapy: a randomized controlled study

World Journal of Urology, August 2020

PSA testing patterns in a large Swedish cohort before the implementation of organized PSA testing

Scandinavian Journal of Urology, July 2020

Machine learning-based analysis of [18F]DCFPyL PET radiomics for risk stratification in primary prostate cancer

European Journal of Nuclear Medicine and Molecular Imaging, July 2020

Retzius-sparing robot-assisted radical prostatectomy leads to durable improvement in urinary function and quality of life versus standard robot-assisted radical prostatectomy without compromise on oncologic efficacy: single-surgeon series and step-by-step guide

European Urology, June 2020

Development and validation of a deep learning algorithm for gleason grading of prostate cancer from biopsy specimens

JAMA Oncology, July 2020

The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer

British Journal of Cancer, July 2020

68 Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer

European Journal of Nuclear Medicine and Molecular Imaging 2020 Jul 28, July 2020

Treatment of metastasized prostate cancer beyond progression after upfront docetaxel – A real-world data assessment

European Urology Focus, July 2020

Complications after open and robotic‐assisted radical prostatectomy and association with post‐operative opioid use: an analysis of data from the PREVENTER trial

BJU International, July 2020

Long-term outcomes of salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: Not as good as previously thought

European Urology, July 2020

PreviousNext